西安杨森-话题@MedSci

#西安杨森#

23篇内容 | 1618人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1424984, encodeId=3d34142498486, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=西安杨森前高管樊杰赴任梅斯医学CEO, objectType=article, longId=299923, objectId=939729992364, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=939729992364, replyNumber=0, likeNumber=125, createdTime=2022-03-04, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=939729992364, moduleTitle=西安杨森前高管樊杰赴任梅斯医学CEO, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=939729992364)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424983, encodeId=aad51424983e2, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=梅斯医学与西安杨森爱可泰隆签署战略合作，共同推动罕见病领域认知与诊疗水平, objectType=article, longId=220573, objectId=60602205e3e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60602205e3e4, replyNumber=0, likeNumber=73, createdTime=2021-11-20, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60602205e3e4, moduleTitle=梅斯医学与西安杨森爱可泰隆签署战略合作，共同推动罕见病领域认知与诊疗水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60602205e3e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424982, encodeId=aa0a1424982cc, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=实践前腺专题-加强指南宣讲，促进规范诊疗-西安杨森, objectType=article, longId=216414, objectId=ed0a216414f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed0a216414f3, replyNumber=0, likeNumber=54, createdTime=2021-08-30, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed0a216414f3, moduleTitle=实践前腺专题-加强指南宣讲，促进规范诊疗-西安杨森, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed0a216414f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424981, encodeId=a62d142498108, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=斑块状银屑病重大进展！西安杨森Tremfya(特诺雅，古塞奇尤单抗)获国家药监局(NMPA)批准上市！, objectType=article, longId=192695, objectId=249d19269580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=249d19269580, replyNumber=0, likeNumber=71, createdTime=2020-04-23, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=249d19269580, moduleTitle=斑块状银屑病重大进展！西安杨森Tremfya(特诺雅，古塞奇尤单抗)获国家药监局(NMPA)批准上市！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=249d19269580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424980, encodeId=b6c6142498097, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=银屑病临床急需药物，西安杨森古塞奇尤单抗注射液在华获批, objectType=article, longId=185462, objectId=7bae18546288, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bae18546288, replyNumber=0, likeNumber=85, createdTime=2020-01-01, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bae18546288, moduleTitle=银屑病临床急需药物，西安杨森古塞奇尤单抗注射液在华获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bae18546288)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424979, encodeId=90f314249e957, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=西安杨森宣布旗下新一代前列腺癌治疗方案安森珂®在华获批, objectType=article, longId=183746, objectId=ed7f183e4699, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed7f183e4699, replyNumber=0, likeNumber=94, createdTime=2019-11-30, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed7f183e4699, moduleTitle=西安杨森宣布旗下新一代前列腺癌治疗方案安森珂®在华获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed7f183e4699)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424978, encodeId=fb1914249e854, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=西安杨森宣布旗下新一代雄激素受体抑制剂安森珂(R)在华上市, objectType=article, longId=183710, objectId=6798183e1036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6798183e1036, replyNumber=0, likeNumber=85, createdTime=2019-11-29, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6798183e1036, moduleTitle=西安杨森宣布旗下新一代雄激素受体抑制剂安森珂(R)在华上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6798183e1036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424977, encodeId=003514249e76e, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=西安杨森宣布全球CD38单克隆抗体靶向药物兆珂(R)在中国上市, objectType=article, longId=181322, objectId=2ee818132282, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ee818132282, replyNumber=0, likeNumber=78, createdTime=2019-10-17, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ee818132282, moduleTitle=西安杨森宣布全球CD38单克隆抗体靶向药物兆珂(R)在中国上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ee818132282)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424976, encodeId=f4c614249e6fd, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=全新作用机制开创骨髓瘤治疗新时代西安杨森宣布全球CD38单克隆抗体靶向药物兆珂®在中国上市, objectType=article, longId=181286, objectId=6a1418128699, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a1418128699, replyNumber=0, likeNumber=68, createdTime=2019-10-17, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a1418128699, moduleTitle=全新作用机制开创骨髓瘤治疗新时代西安杨森宣布全球CD38单克隆抗体靶向药物兆珂®在中国上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a1418128699)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424975, encodeId=dedd14249e586, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=世界精神卫生日西安杨森呼吁全社会接纳精神障碍患者, objectType=article, longId=180939, objectId=9c6318093902, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c6318093902, replyNumber=0, likeNumber=67, createdTime=2019-10-12, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c6318093902, moduleTitle=世界精神卫生日西安杨森呼吁全社会接纳精神障碍患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c6318093902)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424974, encodeId=282314249e4ee, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=西安杨森宣布国内每三月皮下注射一次治疗银屑病生物制剂喜达诺®上市, objectType=article, longId=167787, objectId=f96e16e787c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f96e16e787c7, replyNumber=0, likeNumber=92, createdTime=2019-06-08, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f96e16e787c7, moduleTitle=西安杨森宣布国内每三月皮下注射一次治疗银屑病生物制剂喜达诺®上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f96e16e787c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424973, encodeId=7acd14249e356, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=西安杨森旗下类克为中国溃疡性结肠炎提供生物制剂新选择, objectType=article, longId=160429, objectId=fcac16042929, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcac16042929, replyNumber=0, likeNumber=101, createdTime=2019-02-20, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcac16042929, moduleTitle=西安杨森旗下类克为中国溃疡性结肠炎提供生物制剂新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcac16042929)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424972, encodeId=654b14249e231, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=西安杨森两款艾滋病创新药物恩临和普泽力宣布在华上市, objectType=article, longId=154280, objectId=28011542800a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28011542800a, replyNumber=0, likeNumber=104, createdTime=2018-11-25, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28011542800a, moduleTitle=西安杨森两款艾滋病创新药物恩临和普泽力宣布在华上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28011542800a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424971, encodeId=d3d214249e1c7, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=美国强生旗下西安杨森总裁：中国正从制药大国向创新大国改变, objectType=article, longId=152754, objectId=31a7152e5491, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31a7152e5491, replyNumber=0, likeNumber=73, createdTime=2018-11-06, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31a7152e5491, moduleTitle=美国强生旗下西安杨森总裁：中国正从制药大国向创新大国改变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31a7152e5491)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424970, encodeId=87a614249e03d, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=西安杨森欧洲申请将依他胺鼻腔喷雾剂用于治疗抑郁症, objectType=article, longId=150823, objectId=29c0150823ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29c0150823ef, replyNumber=0, likeNumber=99, createdTime=2018-10-13, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29c0150823ef, moduleTitle=西安杨森欧洲申请将依他胺鼻腔喷雾剂用于治疗抑郁症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29c0150823ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424969, encodeId=2db614249694f, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=西安杨森宣布治疗精神分裂症的长效针剂善妥达在中国上市, objectType=article, longId=148860, objectId=fc1b1488604d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc1b1488604d, replyNumber=0, likeNumber=95, createdTime=2018-09-16, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc1b1488604d, moduleTitle=西安杨森宣布治疗精神分裂症的长效针剂善妥达在中国上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc1b1488604d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424968, encodeId=6a4d142496883, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=西安杨森旗下亿珂®获批适应症扩展用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤, objectType=article, longId=144842, objectId=fd5514484242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd5514484242, replyNumber=0, likeNumber=118, createdTime=2018-07-22, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd5514484242, moduleTitle=西安杨森旗下亿珂®获批适应症扩展用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd5514484242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424967, encodeId=e79d142496ee2, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=西安杨森上市国内**每月皮下注射一次抗风湿生物制剂欣普尼, objectType=article, longId=141331, objectId=b2131413318b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2131413318b, replyNumber=0, likeNumber=66, createdTime=2018-06-24, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2131413318b, moduleTitle=西安杨森上市国内**每月皮下注射一次抗风湿生物制剂欣普尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2131413318b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424966, encodeId=14e1142496610, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=西安杨森治疗精神分裂症长效针剂善妥达®获批！, objectType=article, longId=139162, objectId=21ea139162ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21ea139162ea, replyNumber=0, likeNumber=99, createdTime=2018-05-27, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21ea139162ea, moduleTitle=西安杨森治疗精神分裂症长效针剂善妥达®获批！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21ea139162ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1424965, encodeId=28fd1424965c1, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, objectTitle=西安杨森抗风湿免疫病皮下注射生物制剂欣普尼®在中国获批, objectType=article, longId=125572, objectId=5dcf1255e2c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5dcf1255e2c7, replyNumber=0, likeNumber=109, createdTime=2018-01-06, rootId=0, userName=qindq, userId=f7a73942387, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5dcf1255e2c7, moduleTitle=西安杨森抗风湿免疫病皮下注射生物制剂欣普尼®在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5dcf1255e2c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

西安杨森

2020-05-29

qindq (审核中...)

前往app查看评论内容

#西安杨森#

西安杨森前高管樊杰赴任梅斯医学CEO

2022-03-04

qindq (审核中...)

前往app查看评论内容

#西安杨森#

梅斯医学与西安杨森爱可泰隆签署战略合作，共同推动罕见病领域认知与诊疗水平

2021-11-20

qindq (审核中...)

前往app查看评论内容

#西安杨森#

实践前腺专题-加强指南宣讲，促进规范诊疗-西安杨森

2021-08-30

qindq (审核中...)

前往app查看评论内容

#西安杨森#

斑块状银屑病重大进展！西安杨森Tremfya(特诺雅，古塞奇尤单抗)获国家药监局(NMPA)批准上市！

2020-04-23

qindq (审核中...)

前往app查看评论内容

#西安杨森#

银屑病临床急需药物，西安杨森古塞奇尤单抗注射液在华获批

2020-01-01

qindq (审核中...)

前往app查看评论内容

#西安杨森#

西安杨森宣布旗下新一代前列腺癌治疗方案安森珂®在华获批

2019-11-30

qindq (审核中...)

前往app查看评论内容

#西安杨森#

西安杨森宣布旗下新一代雄激素受体抑制剂安森珂(R)在华上市

2019-11-29

qindq (审核中...)

前往app查看评论内容

#西安杨森#

西安杨森宣布全球CD38单克隆抗体靶向药物兆珂(R)在中国上市

2019-10-17

qindq (审核中...)

前往app查看评论内容

#西安杨森#

全新作用机制开创骨髓瘤治疗新时代西安杨森宣布全球CD38单克隆抗体靶向药物兆珂®在中国上市

2019-10-17

qindq (审核中...)

前往app查看评论内容

#西安杨森#

世界精神卫生日西安杨森呼吁全社会接纳精神障碍患者

2019-10-12

qindq (审核中...)

前往app查看评论内容

#西安杨森#

西安杨森宣布国内每三月皮下注射一次治疗银屑病生物制剂喜达诺®上市

2019-06-08

qindq (审核中...)

前往app查看评论内容

#西安杨森#

西安杨森旗下类克为中国溃疡性结肠炎提供生物制剂新选择

2019-02-20

qindq (审核中...)

前往app查看评论内容

#西安杨森#

西安杨森两款艾滋病创新药物恩临和普泽力宣布在华上市

2018-11-25

qindq (审核中...)

前往app查看评论内容

#西安杨森#

美国强生旗下西安杨森总裁：中国正从制药大国向创新大国改变

2018-11-06

qindq (审核中...)

前往app查看评论内容

#西安杨森#

西安杨森欧洲申请将依他胺鼻腔喷雾剂用于治疗抑郁症

2018-10-13

qindq (审核中...)

前往app查看评论内容

#西安杨森#

西安杨森宣布治疗精神分裂症的长效针剂善妥达在中国上市

2018-09-16

qindq (审核中...)

前往app查看评论内容

#西安杨森#

西安杨森旗下亿珂®获批适应症扩展用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤

2018-07-22

qindq (审核中...)

前往app查看评论内容

#西安杨森#

西安杨森上市国内**每月皮下注射一次抗风湿生物制剂欣普尼

2018-06-24

qindq (审核中...)

前往app查看评论内容

#西安杨森#

西安杨森治疗精神分裂症长效针剂善妥达®获批！

2018-05-27

qindq (审核中...)

前往app查看评论内容

#西安杨森#

西安杨森抗风湿免疫病皮下注射生物制剂欣普尼®在中国获批

2018-01-06

科室
- - 订阅+
  - 更多科室
工具
服务